查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403420

2030 年短腸症候群市場預測：按診斷、治療方法、藥物類別、配銷通路和地區進行的全球分析

Short Bowel Syndrome Market Forecasts to 2030 - Global Analysis By Diagnosis (Blood Tests, Imaging Procedures, Physical Exam and Other Diagnoses),Treatment, Drug Class, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球短腸症候群市場規模為 18 億美元，預計在預測期內複合年成長率為 17.9%，到 2030 年將達到 57 億美元。

小腸或大腸的某些部分可能會消失或停止功能，導致一種稱為短腸症候群的複雜疾病。因此，小腸症候群患者經常出現吸收不良，即脂肪、碳水化合物（糖）、維生素、礦物質、微量元素和水等營養素的吸收減少。缺乏重要的維生素和礦物質可能會導致營養不良、體重意外減輕和其他症狀。

根據 WebMD LLC 2021 年發布的資料，每人每年的腸外支持費用約為 65,000 美元至 320,000 美元。

促生長因素：靜脈輸液需求增加

患有這種疾病的患者越來越需要靜脈補液以維持正常的尿流量和水合水平。由於這些患者面臨的挑戰，業內許多知名公司正在努力滿足這項需求。由於髂骨的缺陷會導致鎂吸收不良並導致低鎂血症，因此許多公司開發了鎂補充品來幫助患者保持充足的水分。

成長抑制因素：危險的副作用

市場面臨的主要障礙是用於治療短腸症候群的藥物的副作用。 Revestive 和 Gatex 最典型的健康副作用包括頭痛、噁心、嘔吐、感冒和流感。此外，這些藥物已被證明能夠引起其他健康問題，如大腸息肉、膽囊發炎、胰臟阻塞、可能變成癌症的細胞異常發育和腸阻塞。

機會：短腸症候群的盛行率

近年來，短腸症候群變得越來越常見。給藥全腸外營養的患者數量正在增加，這推動了市場的擴張。短腸症候群的發生率估計為每 100 萬人 4 例，但實際發生率接近每 100 萬人 3 例。接受腸外營養的大量患者預測了這種疾病的確切盛行率，但這尚不清楚。

威脅：治療費用高

腸外營養是治療方法這種疾病最受歡迎的方法，但價格昂貴。腸外營養治療可以在醫院或家中進行。另一方面，在家接受腸外營養的患者的治療費用低於在醫院接受腸外營養的患者。此外，用於治療這種疾病的藥物每年的高昂費用進一步限制了商業性接受度。

COVID-19 的影響

由於這項發現，短腸症候群市場的製造商正在擴大其收入前景，因為 COVID-19 患者報告出現胃腸道問題。另一方面，SBS治療需要長期腸外營養或器官移植。因此，企業和學術界應該共同努力，進一步發展自組織工程研究領域，以實現利用患者自身細胞和組織進行治療。公司正在增加生長激素、低動力藥物和抗胰泌素藥物的產量。

在預測期內，谷氨醯胺部分預計將是最大的。

預計谷氨醯胺細分市場在預測期內將達到最高水準。一種稱為麩醯胺酸的胺基酸是腸道細胞的主要能源來源。麩醯胺酸支持腸道屏障功能，有助於維持腸道黏膜完整性，也可能降低腸道滲透性。它可以透過促進腸道組織修復和縮短腸道手術後的恢復期來促進癒合。

藥物治療產業預計在預測期內複合年成長率最高

預計藥物治療領域在預測期內複合年成長率最高。藥物可以幫助緩解與這種疾病相關的常見症狀，例如腹脹、腹瀉、胃部不適和營養不良。某些藥物可以透過改善營養物質和電解質的吸收來補償腸道功能表面積的損失。這有助於防止營養不良及其後果。

比最大的地區

由於久坐生活方式的增加、醫療基礎設施的改善以及政府對克隆氏症研究的資助增加，預計北美將在預測期內佔據最大的市場佔有率。近年來，由於久坐生活方式的發展，短腸症候群的使用顯著增加，導致專注於健康用餐，垃圾食物增加。因此，腸病市場持續成長。

複合年成長率最高的地區

預計亞太地區在預測期內複合年成長率最高。該地區正經歷大公司的直接存在、對新療法市場開拓的大量研發投資以及對基於 GLP-2 的療法的臨床試驗的日益重視，這些因素正在推動市場成長。推動市場擴張的主要原因是短腸症候群患者數量的顯著增加（尤其是在新興國家）、快速都市化以及政府在醫療基礎設施方面的支出增加。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 公司之間的競爭關係

第5章全球短腸症候群市場：依藥物類別

  • 麩醯胺酸
  • GLP-2
  • 生長激素
  • 佐爾布蒂夫
  • 質子幫浦抑制劑
  • 組織胺阻斷劑
  • 升糖素
  • 止瀉
  • 其他藥物類別

第6章全球短腸症候群市場：依配銷通路

  • 零售藥房
  • 醫院藥房
  • 網上銷售

第7章全球短腸症候群市場：依診斷

  • 驗血
  • 影像檢查
    • 磁振造影(MRI)
    • 使用顯影劑的X 光攝影
    • 電腦斷層掃描 (CT) 掃描
  • 體檢
  • 其他診斷

第8章全球短腸症候群市場：依治療方法

  • 藥品
  • 外科手術
  • 營養療法
    • 經腸營養
    • 腸外營養
  • 移植
  • 其他治療方法

第9章全球短腸症候群市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • VectivBio AG
  • Takeda Pharmaceutical Company Limited
  • Nutrinia
  • Merck KGaA
  • Ardelyx
  • OxThera Inc
  • Zealand Pharma
  • Nestle Health Science
  • Hanmi Pharm.Co., Ltd
  • Sancilio&Company Inc
  • Meters Biopharma
  • OPKO Health, Inc.
Product Code: SMRC24645

According to Stratistics MRC, the Global Short Bowel Syndrome Market is accounted for $1.8 billion in 2023 and is expected to reach $5.7 billion by 2030 growing at a CAGR of 17.9% during the forecast period. A part of the small or large intestine may physically disappear or cease to function, resulting in the complicated condition known as short bowel syndrome. As a result, malabsorption-the decreased absorption of nutrients such as lipids, carbohydrates (sugars), vitamins, minerals, trace elements, and fluids-occurs often in people with small bowel syndrome. Malnutrition, inadvertent weight loss, and other symptoms might result from the deficiency of vital vitamins and minerals.

According to the data published by WebMD LLC in 2021, the cost of parenteral support per person is around USD 65,000 to USD 320,000 annually.

Market Dynamics:

Driver:

Increased demand of intravenous supplementation of fluids

Patients with this disease are increasingly requiring intravenous fluid supplementation to maintain normal urine flow and hydration levels. Given that these individuals have difficulties, a number of prominent firms in the industry are attempting to address this need. Since the loss of the distal ileum results in malabsorption of magnesium, which causes hypomagnesemia, a number of firms are creating magnesium supplements to aid patients in getting enough water.

Restraint:

Dangerous side effects

The main obstacle facing the market is the adverse effects of medications used to treat short bowel syndrome. The most typical side effects of Revestive or Gattex on health include headaches, nausea, vomiting, colds, and flu. Furthermore, it has been shown that these medications may result in other health issues such colon polyps, gallbladder inflammation, pancreatic obstruction, aberrant cell development that may result in cancer, and intestinal blockage.

Opportunity:

Prevalence of short bowel syndrome

Short bowel syndrome has become more common in recent years. The number of patients receiving complete parenteral nutrition is growing, which has fueled market expansion. The estimated incidence of short bowel syndrome is four cases per million, although actual incidence is closer to three cases per million. Given the amount of patients receiving parenteral nourishment, the disease's precise prevalence is predicted, despite the lack of clarity in this regard.

Threat:

High treatment cost

The most popular therapy for treating this illness is parenteral feeding, which comes with a high expense for the entire course of care. Both in-hospital and at-home environments can perform this treatment. On the other hand, compared to patients getting parenteral nourishment in hospitals, the cost of care for those receiving it at home is lower. Furthermore, the prohibitive yearly expense of the medications used to treat this illness further restricts their commercial acceptance.

COVID-19 Impact:

Manufacturers in the short bowel syndrome market are expanding their income prospects as a result of the results, since individuals with COVID-19 have reported experiencing gastrointestinal issues. On the other hand, long-term parenteral feeding or an organ transplant are necessary for the SBS therapy. Thus, businesses and academics ought to work together to further the field of autologous tissue engineering research, which enables patients to be treated with their own cells or tissues. Businesses are increasing their production of growth hormones, hypomotility drugs and anti-secretin medicines.

The glutamine segment is expected to be the largest during the forecast period

The glutamine segment is expected to be the largest during the forecast period. An amino acid called glutamine is the main energy source for the intestinal lining cells. It supports the operation of the gut barrier, aids in preserving the integrity of the intestinal mucosa, and may even lessen intestinal permeability. By encouraging the repair of the intestinal tissues and shortening the recovery period following intestinal surgery, it may facilitate recuperation.

The medications segment is expected to have the highest CAGR during the forecast period

The medications segment is expected to have the highest CAGR during the forecast period. Drugs can aid in the relief of symptoms including bloating, diarrhea, stomach discomfort, and nutritional deficits that are frequently linked to this illness. Certain drugs can make up for the decreased functional surface area of the gut by improving the absorption of nutrients and electrolytes. This aids in the prevention of malnutrition and its consequences.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the increased sedentary lifestyle, increased healthcare infrastructure, and rising funding from the government on the research of Crohn's disease, among others. The use of short bowel syndrome has expanded significantly in recent years due to the development in sedentary lifestyles, which have left people with less time to focus on eating wholesome foods and more junk food. As a result, the market for intestinal diseases has continued to grow.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The market is growing in this area due to the direct presence of large companies, significant R&D investments in the development of novel medications, and an increasing emphasis on clinical trials for GLP-2-based therapies. The primary reasons propelling the market expansion are the notable increase in short bowel syndrome cases, especially in emerging nations, rapid urbanization, and rising government spending on healthcare infrastructure.

Key players in the market:

Some of the key players in Short Bowel Syndrome market include VectivBio AG, Takeda Pharmaceutical Company Limited, Nutrinia, Merck KGaA, Ardelyx, OxThera Inc, Zealand Pharma, Nestle Health Science, Hanmi Pharm.Co., Ltd, Sancilio&Company Inc, Meters Biopharma and OPKO Health, Inc.

Key Developments:

In September 2022, Zealand Pharma A/S announced positive results from a phase 3 trial of Glepaglutide for treatment of short bowel syndrome. Glepaglutide is the potential best-in-class long-acting GLP-2 analog. The candidate has distinct advantages over Teduglutide, including once-weekly dosing and a longer half-life.

In March 2022, VectivBio AG announced a licensing agreement with Asahi Kasei Pharma Corporation to commercialize and develop apraglutide in Japan, which is used to treat SBS.

Diagnoses Covered:

  • Blood Tests
  • Imaging Procedures
  • Physical Exam
  • Other Diagnoses

Treatments Covered:

  • Medications
  • Surgery
  • Nutritional Therapy
  • Transplant
  • Other Treatments

Drug Classes Covered:

  • Glutamine
  • GLP-2
  • Growth Hormone
  • Zorbtive
  • Proton Pump Inhibitors
  • Histamine Blockers
  • Glucagon
  • Anti-Diarrheals
  • Other Drug Classes

Distribution Channels Covered:

  • Medications
  • Surgery
  • Nutritional Therapy
  • Transplant
  • Other Treatments

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Short Bowel Syndrome Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Glutamine
  • 5.3 GLP-2
  • 5.4 Growth Hormone
  • 5.5 Zorbtive
  • 5.6 Proton Pump Inhibitors
  • 5.7 Histamine Blockers
  • 5.8 Glucagon
  • 5.9 Anti-Diarrheals
  • 5.10 Other Drug Classes

6 Global Short Bowel Syndrome Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Retail Pharmacies
  • 6.3 Hospital Pharmacies
  • 6.4 Online Sales

7 Global Short Bowel Syndrome Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Blood Tests
  • 7.3 Imaging Procedures
    • 7.3.1 Magnetic Resonance Imaging (MRI)
    • 7.3.2 X-ray with a Contrast Material
    • 7.3.2 Computerized Tomography (CT) Scan
  • 7.4 Physical Exam
  • 7.5 Other Diagnoses

8 Global Short Bowel Syndrome Market, By Treatment

  • 8.1 Introduction
  • 8.2 Medications
  • 8.3 Surgery
  • 8.4 Nutritional Therapy
    • 8.4.1 Enteral Nutrition
    • 8.4.2 Parenteral Nutrition
  • 8.5 Transplant
  • 8.6 Other Treatments

9 Global Short Bowel Syndrome Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 VectivBio AG
  • 11.2 Takeda Pharmaceutical Company Limited
  • 11.3 Nutrinia
  • 11.4 Merck KGaA
  • 11.5 Ardelyx
  • 11.6 OxThera Inc
  • 11.7 Zealand Pharma
  • 11.8 Nestle Health Science
  • 11.9 Hanmi Pharm.Co., Ltd
  • 11.10 Sancilio&Company Inc
  • 11.11 Meters Biopharma
  • 11.12 OPKO Health, Inc.

List of Tables

  • Table 1 Global Short Bowel Syndrome Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Short Bowel Syndrome Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Short Bowel Syndrome Market Outlook, By Glutamine (2021-2030) ($MN)
  • Table 4 Global Short Bowel Syndrome Market Outlook, By GLP-2 (2021-2030) ($MN)
  • Table 5 Global Short Bowel Syndrome Market Outlook, By Growth Hormone (2021-2030) ($MN)
  • Table 6 Global Short Bowel Syndrome Market Outlook, By Zorbtive (2021-2030) ($MN)
  • Table 7 Global Short Bowel Syndrome Market Outlook, By Proton Pump Inhibitors (2021-2030) ($MN)
  • Table 8 Global Short Bowel Syndrome Market Outlook, By Histamine Blockers (2021-2030) ($MN)
  • Table 9 Global Short Bowel Syndrome Market Outlook, By Glucagon (2021-2030) ($MN)
  • Table 10 Global Short Bowel Syndrome Market Outlook, By Anti-Diarrheals (2021-2030) ($MN)
  • Table 11 Global Short Bowel Syndrome Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 12 Global Short Bowel Syndrome Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Short Bowel Syndrome Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 14 Global Short Bowel Syndrome Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 15 Global Short Bowel Syndrome Market Outlook, By Online Sales (2021-2030) ($MN)
  • Table 16 Global Short Bowel Syndrome Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 17 Global Short Bowel Syndrome Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 18 Global Short Bowel Syndrome Market Outlook, By Imaging Procedures (2021-2030) ($MN)
  • Table 19 Global Short Bowel Syndrome Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 20 Global Short Bowel Syndrome Market Outlook, By X-ray with a Contrast Material (2021-2030) ($MN)
  • Table 21 Global Short Bowel Syndrome Market Outlook, By Computerized Tomography (CT) Scan (2021-2030) ($MN)
  • Table 22 Global Short Bowel Syndrome Market Outlook, By Physical Exam (2021-2030) ($MN)
  • Table 23 Global Short Bowel Syndrome Market Outlook, By Other Diagnoses (2021-2030) ($MN)
  • Table 24 Global Short Bowel Syndrome Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 25 Global Short Bowel Syndrome Market Outlook, By Medications (2021-2030) ($MN)
  • Table 26 Global Short Bowel Syndrome Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 27 Global Short Bowel Syndrome Market Outlook, By Nutritional Therapy (2021-2030) ($MN)
  • Table 28 Global Short Bowel Syndrome Market Outlook, By Enteral Nutrition (2021-2030) ($MN)
  • Table 29 Global Short Bowel Syndrome Market Outlook, By Parenteral Nutrition (2021-2030) ($MN)
  • Table 30 Global Short Bowel Syndrome Market Outlook, By Transplant (2021-2030) ($MN)
  • Table 31 Global Short Bowel Syndrome Market Outlook, By Other Treatments (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.